Licensing · Global (LMICs) · Announced 19 Nov 2026

Innogen Pharmaceuticals → Arcera Life Sciences

HKEX-listed Innogen granted Abu Dhabi-based Arcera exclusive rights to commercialise its long-acting GLP-1 efsubaglutide alfa in selected Middle East (incl. UAE), African, Eastern European and Latin American markets, for an undisclosed upfront plus milestones and royalties.

Parties: Innogen Pharmaceuticals (China) → Arcera Life Sciences (United Arab Emirates)

Deal type
Licensing
Value
Undisclosed
Territory
Selected countries in the Middle East (including the UAE), Africa, Eastern Europe and Latin America; countries not listed
Therapeutic area
Metabolic / Diabetes
Asset
efsubaglutide alfa
Announced
19 Nov 2026

Our analysis

Why this matters

Arcera Life Sciences and Innogen Pharmaceuticals announced on 19 November 2026 an exclusive licensing and commercialisation agreement for Efsubaglutide Alfa, Innogen's GLP-1 receptor agonist. Arcera gets the rights in selected countries across the Middle East (including the UAE), Africa, Eastern Europe and Latin America; the countries were not listed. Innogen receives an upfront payment and is eligible for milestones and tiered royalties on net sales. No amounts were disclosed. Commercialisation starts once local regulatory approvals are obtained.

Efsubaglutide Alfa is a fusion of a human GLP-1 analogue with an IgG Fc fragment. It is approved for type 2 diabetes in mainland China and Macao and is on China's National Reimbursement Drug List. Innogen reports an HbA1c reduction of about 2.2 percentage points at week 24, average weight loss of 10.6% at 18 weeks with once-weekly dosing in Chinese adults with overweight or obesity, and a Phase II study in Australia testing once-monthly dosing.

The full analysis is free to read with a work email on this page.

Source: Arcera Life Sciences press release

More deals involving Innogen Pharmaceuticals or Arcera Life Sciences

Latest deals

All Global (LMICs) deals → · All licensing deals → · Browse all emerging-market pharma deals →